Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 2018 to See Transition to “Leap Phase” in Kyowa Kirin’s Midterm Plan: President
February 13, 2018
- Hiroshima Couple Arrested for Counterfeit Harvoni Case
February 9, 2018
- Nipro Grabs Rights to TC BioPharm’s CAR-T Therapy
February 9, 2018
- Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
February 9, 2018
- Ethical Drug Sales Up 2.1% in December on Cancer Meds, SGLT2
February 9, 2018
- Hisamitsu to Form Hong Kong Subsidiary to Step Up Salonpas, Mohrus Sales
February 9, 2018
- Otsuka Ups 2017 Profit Estimate on US Tax Reform
February 9, 2018
- Positive RA Data Out for JAK Inhibitor Peficitinib, Astellas Gears Up for Filing
February 9, 2018
- Fujifilm, Takeda Strike Deal on iPS Cell-Based Heart Therapy
February 9, 2018
- YL Biologics’ Enbrel Biosimilar Shows Equivalent Efficacy to Originator
February 8, 2018
- Daiichi Sankyo’s ADC U3-1402 Enters PI Study in US for NSCLC, Eyeing Its Multinational Study
February 8, 2018
- Torii Enjoys Earnings Rise on New HIV Drugs
February 7, 2018
- Xtandi Cuts Risk of Metastasis or Deaths by 71% in Non-Metastatic CRPC
February 7, 2018
- EA Pharma Launches Rectabul, Boosts Efforts on Humira to Gird for IBD Showdown
February 7, 2018
- Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
- PorMedTec to Support Development Using Disease Model Pigs, Clients Already Include One Major Drug Maker
February 6, 2018
- Asahi Kasei Rolls Out Sanofi’s RA Med Kevzara
February 6, 2018
- Tagrisso Put on Priority Path in Japan for 1st-Line EGFR-Mutated NSCLC
February 6, 2018
- Japan Ethical Drug Market Projected at 9.6 Trillion Yen in 2024: Fuji Keizai
February 5, 2018
- Keiko Oishi to Head CMIC Holdings from April 1, with Pres. Nakamura Continuing as Chairman and CEO
February 5, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…